| Literature DB >> 28176844 |
Rong Zhang1,2, Michael Knapp3, Kentaro Suzuki4, Daiki Kajioka4, Johanna M Schmidt1,5, Jonas Winkler5, Öznur Yilmaz5, Michael Pleschka5, Jia Cao6, Christina Clementson Kockum7, Gillian Barker8, Gundela Holmdahl9, Glenda Beaman10, David Keene11, Adrian S Woolf12,13, Raimondo M Cervellione11, Wei Cheng14,15,16, Simon Wilkins17,18, John P Gearhart19, Fabio Sirchia20, Massimo Di Grazia21, Anne-Karolin Ebert22, Wolfgang Rösch23, Jörg Ellinger24, Ekkehart Jenetzky25,26, Nadine Zwink25, Wout F Feitz27, Carlo Marcelis28, Johannes Schumacher1, Federico Martinón-Torres29,30, Martin Lloyd Hibberd31, Chiea Chuen Khor32, Stefanie Heilmann-Heimbach1,2, Sandra Barth1,2, Simeon A Boyadjiev32, Alfredo Brusco20, Michael Ludwig33, William Newman10, Agneta Nordenskjöld6,34, Gen Yamada4, Benjamin Odermatt5, Heiko Reutter1,35.
Abstract
Previously genome-wide association methods in patients with classic bladder exstrophy (CBE) found association with ISL1, a master control gene expressed in pericloacal mesenchyme. This study sought to further explore the genetics in a larger set of patients following-up on the most promising genomic regions previously reported. Genotypes of 12 markers obtained from 268 CBE patients of Australian, British, German Italian, Spanish and Swedish origin and 1,354 ethnically matched controls and from 92 CBE case-parent trios from North America were analysed. Only marker rs6874700 at the ISL1 locus showed association (p = 2.22 × 10-08). A meta-analysis of rs6874700 of our previous and present study showed a p value of 9.2 × 10-19. Developmental biology models were used to clarify the location of ISL1 activity in the forming urinary tract. Genetic lineage analysis of Isl1-expressing cells by the lineage tracer mouse model showed Isl1-expressing cells in the urinary tract of mouse embryos at E10.5 and distributed in the bladder at E15.5. Expression of isl1 in zebrafish larvae staged 48 hpf was detected in a small region of the developing pronephros. Our study supports ISL1 as a major susceptibility gene for CBE and as a regulator of urinary tract development.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28176844 PMCID: PMC5296905 DOI: 10.1038/srep42170
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Results of the association analyses for cases and controls, the case-parent trios, and the combined meta-analysis.
| SNP | Chromosome/Region | Position | Risk/other allele | Meta-analysis Cases (n = 268) vs. controls (n = 1,354) (AUS/GB/DE/IT/ES/SE) RR (95% CI) | TDT Case-parent trios (n = 92) (North America) RR (95% CI) | Meta-analysis Cases (n = 268), Controls (n = 1,354), Case-parent trios (n = 92) RR (95% CI) | |
|---|---|---|---|---|---|---|---|
| rs1475601 | 1q31.3 | 194,721,655 | G/A | 1.11 (0.60–2.05) | 0.88 (0.32–2.41) | 1.04 (0.61–1.76) | 0.884 |
| rs72748303 | 1q32.2 | 208,973,633 | A/G | 1.54 (0.95–2.52) | 0.71 (0.23–2.25) | 1.37 (0.87–2.15) | 0.170 |
| rs79145914 | 4p14 | 39,490,706 | G/A | 1.26 (0.74–2.14) | 1.75 (0.51–5.98) | 1.33 (0.82–2.15) | 0.254 |
| rs7689350 | 4q13.3 | 76,207,570 | A/C | 0.98 (0.70–1.38) | 2.13 (0.92–4.92) | 1.10 (0.80–1.51) | 0.568 |
| rs1514351 | 6q12 | 68,694,074 | C/T | 1.20 (0.96–1.50) | 0.91 (0.60–1.39) | 1.13 (0.92–1.37) | 0.239 |
| rs117622209 | 6q22.1 | 118,108,159 | C/T | 1.12 (0.64–1.96) | 1.20 (0.37–3.93) | 1.13 (0.69–1.88) | 0.623 |
| rs56189125 | 7p14.3 | 28,855,348 | G/A | 1.05 (0.09–11.78) | 1.67 (0.61–4.59) | 1.56 (0.61–3.96) | 0.353 |
| rs57086087 | 8p11.21 | 40,301,811 | T/C | 1.07 (0.80–1.44) | 1.42 (0.84–2.39) | 1.15 (0.89–1.48) | 0.301 |
| rs10119066 | 9p24.1 | 7,509,895 | T/G | 0.99 (0.66–1.50) | 1.60 (0.52–4.89) | 1.05 (0.71–1.55) | 0.806 |
| rs16917077 | 9p21.1 | 31,532,212 | C/T | 1.39 (0.74–2.59) | 1.38 (0.55–3.42) | 1.38 (0.83–2.32) | 0.215 |
| rs1514921 | 12q21.2 | 79,481,756 | C/T | 1.21 (0.89–1.64) | 1.35 (0.72–2.53) | 1.23 (0.94–1.62) | 0.136 |
Results of our previous meta-analysis and the presently tested sample for the marker rs6874700.
| SNP | Chromosome/Region | Position | Risk/other allele | Previous meta-analysis Draaken | Replication RR (95% CI) | Present meta-analysis RR (95% CI) | |
|---|---|---|---|---|---|---|---|
| rs6874700 | 5q11.2 | 50,701,750 | A/T | 2.17 (1.75–2.70) | 1.75 (1.44–2.13) | 1.93 (1.67–2.23) | 9.2 × 10−19 |
Figure 1(A,B) Lineage analysis of Isl1-expressing cells at E10.5 and E15.5 by whole mount lacZ staining; (A) Contribution of Isl1-expressing cells in mouse embryos at E10.5 (white arrowhead); (B) Contribution of Isl1-expressing cells in mouse embryos at E15.5 (white arrow). (C–H) Lineage analysis of Isl1-expressing cells after administration of tamoxifen (TM) at E7.5–E9.5; (F–H) Mid-sagittal sections of bladder region at E12.5. The arrows and arrowheads indicate the bladder and genital tubercle, respectively. (I–L): Hypoplasia of GT and bladder in Isl1 cKO embryos.
Figure 2WISH against isl1 (antisense 3′-untranslated region-probe; upper row), slc20a1a (middle row) and both probes combined (lower row) on wild-type zfl at 48 hpf.
48 hpf long-pec stage zfl in lateral (left column) and dorsal view (middle column; same fish; scale bar = 500 μm) in the top row are showing isl1 expression amongst other previous described regions also at most anterior regions of the proximal convoluted tubular (PCT; arrows). 25 μm transversal slices sections of the same fish are shown in the right column (scale bar = 150 μm). The orientation of sections is shown with red dashed lines in the corresponding whole mount images. The zfl show a clear isl1 staining in what has previously been described as the developing pancreatic region, and which might well be overlapping with an anterior region of the slc20a1a labeled PCT (black arrow heads). The overlap of isl1 and slc20a1a expression at this region is further supported by the fact that no additional stained area could be found there, when we used both in situ probes simultaneously for staining. Isl1 expression could not be detected in the developing cloaca or proctodeum region (not shown).